trending Market Intelligence /marketintelligence/en/news-insights/trending/WbQKvTPvYDOlxWNoMdSCiQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Equillium's kidney drug gets US FDA fast-track designation for type of lupus

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Equillium's kidney drug gets US FDA fast-track designation for type of lupus

The U.S. Food and Drug Administration has granted fast-track designation to Equillium Inc.'s itolizumab for treating kidney inflammation in lupus patients.

Fast-track designation gives regulatory priority to treatments that show promise, including frequent meetings with the FDA and priority review of the marketing application.

The San Diego-based biotechnology company started a phase 1b study called Equalise in September to evaluate the drug to treat patients with lupus and lupus nephritis.

Lupus is a chronic autoimmune disease that causes damage to the skin, joints and organs. Lupus nephritis specifically involves the kidneys, affecting about 100,000 patients in the U.S.